What These Ratios Tell Us About AstraZeneca plc

AstraZeneca plc (LON:AZN) remains a serious income play, says Roland Head, but near-term growth is unlikely.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Before I decide whether to buy a company’s shares, I always like to look at two core financial ratios — return on equity and net gearing.

These two ratios provide an indication of how successful a company is at generating profits using shareholders’ funds and debt, and they have a strong influence on dividend payments and share price growth.

Today, I’m going to take a look at pharmaceutical firm AstraZeneca (LSE: AZN) (NYSE: AZN.US), to see how attractive it looks on these two measures.

Return on equity

The return a company generates on its shareholders’ funds is known as return on equity, or ROE. Return on equity can be calculated by dividing a company’s annual profit by its equity (ie, the difference between its total assets and its total liabilities) and is expressed as a percentage.

AstraZeneca’s share price has risen by 43% over the last five years, while its dividend has risen by 36%. However, the firm’s return on equity weakened last year, as its profits fell sharply:

AstraZeneca 2008 2009 2010 2011 2012 Average
ROE 39.8% 41.1% 36.7% 43.0% 26.8% 37.5%

What about debt?  

A key weakness of ROE is that it doesn’t show how much debt a company is using to boost its returns. My preferred way of measuring a company’s debt is by looking at its net gearing — the ratio of net debt to equity.

In the table below, I’ve listed Astra’s net gearing and ROE alongside those of its UK peers, Shire and GlaxoSmithKline:

Company Net gearing 5-year
average ROE
Shire -9.3%
(net cash)
24.7%
AstraZeneca 9.8% 37.5%
GlaxoSmithKline 230.1% 51.9%

Astra’s five-year average ROE looks impressive when set alongside its low gearing levels, which are a sharp contrast to Glaxo’s net debt of £15.4bn.

Is Astra a buy?

The only problem with Astra’s impressive past performance is that it isn’t going to be repeated — at least not for a few years.

City analysts expect Astra’s earnings to fall over the next couple of years, as it loses patent protection on several key products. At the same time, the firm will continue to spend on acquisitions to backfill its pipeline of new drugs.

For income seekers, Astra’s 5.7% dividend yield means that the firm must remain a contender. However, while the firm currently trades on a relatively low forward P/E of around 10, with earnings forecast to fall, the share price may follow, at least in the short term.

Overall, I rate Astra as a hold — long-term holders should do well, as should income seekers, but the firm’s sticky patch isn’t over yet.

Finding market-beating returns

Finding shares that can beat the market over a long period is hard, but if you already hold Astra’s stock, then you might be interested in learning about five star shares that have been identified by the Fool’s team of analysts as 5 Shares To Retire On.

I own three of the shares featured in this free report, and I don’t mind admitting they are amongst the most successful investments I’ve ever made.

To find out the identity of these five companies, click here to download your copy of this report now, while it’s still available.

> Roland owns shares in GlaxoSmithKline but does not own shares in any of the other companies mentioned in this article. The Motley Fool has recommended Shire.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Are Anglo American shares like buying £1 coins for 50p?

Jon Smith takes a look at the falling price of Anglo American shares and asks whether they're chronically undervalued or…

Read more »

Close-up of British bank notes
Investing Articles

I’d buy 1,064 shares of this dividend growth stock for £1,000 a year in passive income

Shares in FTSE 100 conglomerate Bunzl come with a 2% yield at today’s prices. But Stephen Wright thinks this is…

Read more »

Growth Shares

Under 50? Here are 3 monster growth stocks to consider for 2024 and beyond

These US-listed growth stocks could deliver blockbuster gains for long-term investors in the years ahead, says Edward Sheldon.

Read more »

Investing Articles

Here’s how much I’d need to invest in Tesco shares for £100 in monthly passive income

Our writer does not own shares of this supermarket for passive income, but how many would he need to buy…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could £200 of Christmas money be used to start buying shares this month?

Our writer reckons if he was a stock market novice, he could put some Christmas money to work and start…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d aim to build a £250 monthly second income in 2024 – and far beyond!

Our writer thinks buying carefully-chosen dividend shares could help him build a second income over the long term. Here's his…

Read more »

Investing Articles

If I’d put £10k into a FTSE 250 tracker 10 years ago, here’s what I’d have now

UK investors love FTSE 250 tracker funds. But have these products been a good investment over the long term? Edward…

Read more »

Risk reward ratio / risk management concept
Investing Articles

I’d use a Stocks and Shares ISA to invest in low-risk equities and let the passive income roll in

Stephen Wright thinks a Stocks and Shares ISA can be a valuable way of generating tax-efficient passive income even for…

Read more »